Oriol Pich

This study shows that genetic background and environmental factors determine the trajectory of cancer evolution in mice, with distinct mutational paths despite similar final tumor states.

The paper investigates how strand-asymmetric processes like replication and transcription influence DNA damage, repair, and mutagenesis, revealing mechanisms that shape cancer genome evolution.

The paper identifies genes driving clonal hematopoiesis by analyzing somatic mutations in blood samples from cancer cohorts, discovering novel candidates and recovering known drivers.

The paper introduces the Cancer LncRNA Census (CLC), a curated resource of lncRNAs with causative roles in cancer, and shows their genomic and evolutionary features.

ActivePathways integrates multivariate omics data to identify enriched pathways, revealing cancer driver genes and prognostic pathways in breast cancer.

This study identifies mutational footprints of six cancer therapies using whole-genome data from metastatic tumors to assess their contribution to mutation burden and risk of driver mutations.

The paper identifies and characterizes coding and non-coding driver mutations across 2,500 cancer genomes, revealing new candidates and questioning previous findings.

This paper identifies driver mutations across 2,500 tumors from 37 cancer types, revealing a whole-genome panorama of genomic events that underlie tumor development.

The paper predicts SNPs affecting drug-protein binding affinities using genomic and drug interaction data, estimating that individuals carry ~6 SNPs impacting ~5 FDA-approved drugs.